Premium
The Effect of Recombinant Insulin‐like Growth Factor I on Ketone Body, Lipid and Apolipoprotein Concentrations and its use to Treat Ketoacidosis in Severe Insulin Resistance
Author(s) -
Quin J. D.,
Smith K.,
Beastall G. H.,
Miell J. P.,
MacCuish A. C.
Publication year - 1994
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1994.tb02042.x
Subject(s) - medicine , ketoacidosis , endocrinology , ketone bodies , insulin , apolipoprotein b , diabetic ketoacidosis , insulin resistance , triglyceride , cholesterol , diabetes mellitus , metabolism , type 1 diabetes
The effect of recombinant insulin‐like growth factor I (rhlGF‐I) on ketone body concentrations was studied in a patient with the Mendenhall syndrome, a rare insulin‐resistant state. Treatment with intravenous rhlGF‐I for an episode of ketoacidosis led to a clinical and biochemical improvement. One month later, the effect of 20 mg rhlGF‐I infused daily for 4 days on ketone body concentrations was studied. From peak concentrations 24 h prior to the study to a nadir 72 h after the infusion commenced, acetoacetate fell from 4.17 mmol l ‐1 to 0.86 mmol l ‐1 , β‐hydroxybutyrate from 9.91 mmol l ‐1 to 2.03 mmol l ‐1 , and acetone from 2 mmol l ‐1 to 0.4 mmol l ‐1 . Further studies of rhlGF‐1 use caused a fall in concentrations of cholesterol, triglyceride, VLDL, LDL, and apolipoprotein B. Infusion of rhlGF‐1 reduces ketone body concentrations and may be life‐saving in the treatment of ketoacidosis developing in a patient with a severe insulin‐resistant state.